相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Hans-Ulrich Haering et al.
DIABETES CARE (2014)
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2014)
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
C. S. Kovacs et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
Hans-Ulrich Haering et al.
DIABETES CARE (2013)
HYPOGLYCEMIA: MINIMIZING ITS IMPACT IN TYPE 2 DIABETES
Etie Moghissi et al.
ENDOCRINE PRACTICE (2013)
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
Jan N. Basile
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Roden et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
Giovanni Musso et al.
ANNALS OF MEDICINE (2012)
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor
Paul Nyirjesy et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
Anthony H. Barnett et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
R. A. DeFronzo et al.
DIABETES OBESITY & METABOLISM (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study
M. Peyrot et al.
DIABETIC MEDICINE (2012)
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. E. Inzucchi et al.
DIABETOLOGIA (2012)
Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database
Ishan Hirji et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2012)
Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)
Ishan Hirji et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2012)
Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes
Stuart A. Ross et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
James F. List et al.
KIDNEY INTERNATIONAL (2011)
Hypoglycemia, Diabetes, and Cardiovascular Events
Cyrus V. Desouza et al.
DIABETES CARE (2010)
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
T. Vilsboll et al.
DIABETES OBESITY & METABOLISM (2010)
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2009)
Insulin Therapy and Type 2 Diabetes: Management of Weight Gain
Samy I. McFarlane
JOURNAL OF CLINICAL HYPERTENSION (2009)
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Barrier of Hypoglycemia in Diabetes
Philip E. Cryer
DIABETES (2008)
Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage? An argument in favor
Matthew C. Riddle
DIABETES CARE (2008)
Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management(RECAP-DM) Study
F. Alvarez Guisasola et al.
DIABETES OBESITY & METABOLISM (2008)
Intensification lessons with modern premixes: From clinical trial to clinical practice
Serdar Guler et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Insulin-associated weight gain in diabetes - causes, effects and coping strategies
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2007)
Insulin treatment and the problem of weight gain in type 2 diabetes
Catherine Carver
DIABETES EDUCATOR (2006)
Psychological insulin resistance in patients with type 2 diabetes - The scope of the problem
WH Polonsky et al.
DIABETES CARE (2005)
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes
HU Janka et al.
DIABETES CARE (2005)
The burden of treatment failure in type 2 diabetes
JB Brown et al.
DIABETES CARE (2004)
The treat-to-target trial - Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
MC Riddle et al.
DIABETES CARE (2003)
Combination therapies with insulin in type 2 diabetes
H Yki-Järvinen
DIABETES CARE (2001)
分享论文
